| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Evgen Pharma to commence trial by October-end to assess respiratory infection treatment in COVID-19 patients
StockMarketWire.com
|
Drug development company Evgen Pharma said all necessary regulatory approvals had now been received to carry out a clinical trial at the end of the month of its lead drug to treat acute respiratory infections in patients with suspected COVID-19.
STAR, phase II/III trial would investigate whether the company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome.
At 9:21am: (LON:EVG) Evgen Pharma Plc share price was +1.25p at 13.63p
Story provided by StockMarketWire.com
|
|
|
|
|
|
